• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printing Applications

    6/28/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials
    Get the next $ZY alert in real time by email

    EMERYVILLE, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use in high performance 3D printing applications. 3D4Makers will convert the powder to filament, offering its first-ever polyimide filament to customers for use across a wide range of applications including aerospace, automotive, and transportation.

    Polyimide is a very high-strength polymer that is inherently flame retardant, has excellent insulating properties and excellent thermal stability. Zymergen Z2 polyimide is easy to 3D print and demonstrates low warp while having significant Z strength. The material has been tested by leading high-temperature 3D printing manufacturers miniFactory, Orion AM, Aon3D, and others.

    Zymergen uses machine learning, genomics, and automation to look for biomolecules that perform better than petroleum-based chemicals. In this way, Zymergen aims to make bioinspired materials that are more efficient and designed to displace petroleum-based materials. Zymergen Z2 polymer has critical advantages for printing parts that require higher tensile strength and improved yield, showing significant improvement in tensile strength over incumbents.

    "We are excited to partner with Zymergen to offer the high performance 3D printing materials to our customers," said Jasper Willie, Co-founder of 3D4Makers. "The ability to 3D print polyimide is a game-changer for the additive manufacturing industry. We believe this material has the potential to out-perform high-performance polymers like PEEK, PPSU and PEI in applications where high strength and high performance temperatures are required."

    "We at miniFactory really understand what our clients need from 3D printers and materials," said Olli Pihlajamäki, COO at miniFactory. "Zymergen's material has given us great results on the printer and testing. We're really enthusiastic about the possibilities it gives to our customers."

    "At Zymergen, we partner with nature to design and produce molecules, microbes, and materials that can enable customers to create breakthrough products," said Jay Flatley, Zymergen's interim Chief Executive Officer. "The market is hungry for a new generation of technology that will transform the way materials are manufactured. We are confident that Zymergen will be a significant contributor to that future."

    The terms of the agreement were not disclosed.

    About Zymergen

    Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world. For more information visit www.zymergen.com.

    About 3D4Makers

    Netherlands-based 3D4Makers is a leader in high-performance 3D printing materials. The company is a material extrusion materials supplier to aviation, space, industrial and medical multinationals worldwide. In addition, racing teams, leading universities, national laboratories, and automotive companies all use 3D4Makers; high tolerance, high-performance filaments such as PEI, PEEK, PEKK, PPSU, PAHT, and more. Read more at https://www.3d4makers.com/

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on the Company's beliefs and assumptions and on information currently available to it on the date of this press release. In some cases, you can identify these statements by forward-looking words such as "may," "will," "continue," "anticipate," "intend," "could," "project," "expect" or the negative or plural of these words or similar expressions. Forward-looking statements in this press release, include but are not limited to statements regarding the potential of our polymers across a wide range of industries, including aerospace, automotive, and transportation and the advantages provided by our polymer for 3D printing parts and our ability to make bioinspired materials that are more efficient and designed to displace petroleum-based materials. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to successfully commercialize or generate revenue from our products; our ability to execute on our new strategic plan and our ability to identify commercial opportunities. These and other risks are described more fully in the Company's filings with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, and other documents the Company subsequently files with the SEC. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Zymergen Investor Contact

    [email protected] 

    3D4Makers Media Contact

    Jasper Wille

    [email protected] 



    Primary Logo

    Get the next $ZY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZY

    DatePrice TargetRatingAnalyst
    3/2/2022Market Perform
    Cowen
    1/12/2022$6.50Reduce → Hold
    HSBC Securities
    10/15/2021Market Perform
    Cowen
    9/27/2021$12.00Neutral → Underweight
    JP Morgan
    8/31/2021$56.00 → $13.00Buy → Neutral
    UBS
    8/4/2021$43.00 → $7.00Buy → Underperform
    BofA Securities
    8/4/2021Outperform → Market Perform
    Cowen & Co.
    8/4/2021$55.00 → $12.00Buy → Neutral
    Goldman Sachs
    More analyst ratings

    $ZY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Bioworks Completes Acquisition of Zymergen

    BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, and Zymergen (NASDAQ:ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome t

    10/19/22 9:08:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Ginkgo to Acquire Zymergen

    Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac

    7/25/22 7:01:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

    EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficiency, and reliability of operations for its existing platform. Octant has now more than doubled its initial investment through the purchase of an additional six RAC units, vastly increasing the system's throughput, capabilities, and ability to run complex workflows. "We've been extremely pleased with the performance of our current RAC System and are l

    7/14/22 4:56:39 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cowen resumed coverage on Zymergen

    Cowen resumed coverage of Zymergen with a rating of Market Perform

    3/2/22 8:44:04 AM ET
    $ZY
    Industrial Specialties
    Industrials

    Zymergen upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Zymergen from Reduce to Hold and set a new price target of $6.50

    1/12/22 7:08:41 AM ET
    $ZY
    Industrial Specialties
    Industrials

    Cowen resumed coverage on Zymergen

    Cowen resumed coverage of Zymergen with a rating of Market Perform

    10/15/21 7:34:23 AM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Financials

    Live finance-specific insights

    View All

    Ginkgo to Acquire Zymergen

    Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac

    7/25/22 7:01:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Zymergen Reports Preliminary First Quarter 2022 Financial Results

    EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the first quarter ended March 31, 2022. "Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process," said Zymergen's interim CEO, Jay Flatley. "We now have the infrastructure to support great execution and the delivery of products across our three businesses of Advanced Materials, Drug Discovery and Automation." Preliminary First Quarter 2022 Financial ResultsTotal r

    5/12/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022

    EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world. Investor Contactinvest

    4/13/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)

    SC 13G/A - Zymergen Inc. (0001645842) (Subject)

    10/21/22 4:31:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form SC 13G filed by Zymergen Inc.

    SC 13G - Zymergen Inc. (0001645842) (Subject)

    2/14/22 3:22:50 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form SC 13G filed by Zymergen Inc.

    SC 13G - Zymergen Inc. (0001645842) (Subject)

    2/14/22 9:36:54 AM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    SEC Filings

    View All

    SEC Form 15-12G filed by Zymergen Inc.

    15-12G - Zymergen Inc. (0001645842) (Filer)

    10/31/22 4:47:58 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form EFFECT filed by Zymergen Inc.

    EFFECT - Zymergen Inc. (0001645842) (Filer)

    10/26/22 12:15:12 AM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form POS AM filed by Zymergen Inc.

    POS AM - Zymergen Inc. (0001645842) (Filer)

    10/19/22 12:36:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Svf Excalibur (Cayman) Ltd disposed of 26,614,219 shares

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/21/22 4:30:20 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form 4: Flatley Jay T returned 144,789 shares to the company, closing all direct ownership in the company

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/19/22 8:17:59 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form 4: Chu Steven returned 50,000 shares to the company, closing all direct ownership in the company

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/19/22 8:15:58 PM ET
    $ZY
    Industrial Specialties
    Industrials